Notable Runner: Can BioScrip Inc’s Tomorrow Be Different? The Stock Increases Again

Notable Runner: Can BioScrip Inc's Tomorrow Be Different? The Stock Increases Again

The stock of BioScrip Inc (NASDAQ:BIOS) is a huge mover today! The stock increased 6.57% or $0.19 during the last trading session, hitting $3.08. About 940,279 shares traded hands or 88.55% up from the average. BioScrip Inc (NASDAQ:BIOS) has risen 33.80% since February 29, 2016 and is uptrending. It has outperformed by 21.58% the S&P500.
The move comes after 9 months positive chart setup for the $350.75M company. It was reported on Oct, 4 by We have $5.82 PT which if reached, will make NASDAQ:BIOS worth $312.17M more.

Analysts await BioScrip Inc (NASDAQ:BIOS) to report earnings on November, 2. They expect $-0.06 EPS, up 68.42% or $0.13 from last year’s $-0.19 per share. After $-0.08 actual EPS reported by BioScrip Inc for the previous quarter, Wall Street now forecasts -25.00% EPS growth.

BioScrip Inc (NASDAQ:BIOS) Ratings Coverage

Out of 2 analysts covering BioScrip (NASDAQ:BIOS), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. BioScrip has been the topic of 2 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Wednesday, August 12 by Dougherty & Company. SunTrust downgraded the shares of BIOS in a report on Tuesday, August 11 to “Buy” rating.

According to Zacks Investment Research, “BioScrip provides comprehensive pharmaceutical care solutions. We partner with healthcare payors, pharmaceutical manufacturers, government agencies, physicians, and patients to deliver cost effective programs that enhance the quality of patient life. We focus our products and services in two core areas: specialty medication distribution and clinical management services, both nationally and community-based and pharmacy benefit management services.”

Insitutional Activity: The institutional sentiment increased to 1.51 in 2016 Q2. Its up 0.36, from 1.15 in 2016Q1. The ratio is positive, as 13 funds sold all BioScrip Inc shares owned while 26 reduced positions. 24 funds bought stakes while 35 increased positions. They now own 92.45 million shares or 63.22% more from 56.64 million shares in 2016Q1.
Nationwide Fund owns 43,271 shares or 0% of their US portfolio. Thompson Siegel And Walmsley Ltd Liability Corp last reported 1,900 shares in the company. Blackrock Institutional Tru Na reported 1.84 million shares or 0% of all its holdings. Moreover, Oxford Asset Mngmt has 0.01% invested in BioScrip Inc (NASDAQ:BIOS) for 68,877 shares. Teton Advsrs last reported 1.14 million shares in the company. Moreover, Goldman Sachs Gru has 0% invested in BioScrip Inc (NASDAQ:BIOS) for 318,147 shares. The North Carolina-based Sheets Smith Wealth Mgmt has invested 0.05% in BioScrip Inc (NASDAQ:BIOS). Deutsche Fincl Bank Ag has 0% invested in the company for 1.06M shares. The Pennsylvania-based Pnc Services Group Inc Incorporated has invested 0% in BioScrip Inc (NASDAQ:BIOS). Ardsley Advisory Prtn last reported 5.42 million shares in the company. Morgan Stanley has 0% invested in the company for 493,774 shares. Moreover, Millrace Asset Gru Inc has 2.26% invested in BioScrip Inc (NASDAQ:BIOS) for 543,862 shares. Aqr Cap Mngmt Ltd last reported 40,616 shares in the company. Prescott Gp Cap Mngmt Lc has 2.24 million shares for 1.37% of their US portfolio. Bnp Paribas Arbitrage Sa, a New York-based fund reported 2,729 shares.

More recent BioScrip Inc (NASDAQ:BIOS) news were published by: which released: “Why Shares of BioScrip, Inc. Are Crashing Today” on May 08, 2015. Also published the news titled: “Moody’s downgrades BioScrip’s CFR to Caa2; outlook stable” on March 03, 2016.‘s news article titled: “BioScrip Announces Transformative Acquisition of Home Solutions That Will …” with publication date: June 13, 2016 was also an interesting one.

BIOS Company Profile

BioScrip, Inc., incorporated on March 22, 1996, is engaged in providing infusion solutions. The Firm partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Firm operates through Infusion Services segment. The Firm operates through approximately 70 service locations in over 30 states. The Firm offers home infusion services to provide clinical management services and the delivery of prescription medications.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment